Table 2.
Depicts the clinical significance of different lncRNAs in ovarian cancer
| lncRNAs in ovarian cancer | Location | Length | Clinical Significance | Reference |
|---|---|---|---|---|
| H19 | Chr11p15.5 | 2.3 | In ovarian cancer, when H19 is highly expressed it triggers migration and invasion of tumor cells | [61] |
| HOTAIR | Chr12.q13.13 | 2.2 | HOTAIR plays crucial role in chemoresistance and its increased sensitivity towards cisplatin causes autophagy in OC | [62] |
| X inactivate-specific transcript (XIST) | ChrX | 17 | XIST is found to be a potent biomarker for patients who respond to first-line chemotherapy because a high affinity is found between regulation of XIST and patient response to chemotherapy using paclitaxel. | [63] |
| UCA1 | Chr19p13.12 | 1439 | UCA1 is a dominant biomarker for several cancer types. Up-regulation of UCA1 is linked with progression-free survival (PFS) in ovarian cancer patients. | (Hong, Hou [64]) |
| MALAT-1 | Chr11q13 | > 8000 nucleotides | Wnt/β-catenin signaling pathway is affected by; HOTAIR, MALAT-1 is, therefore, downregulation of MALAT-1 is used to inhibit OC cell viability, migration, and invasion, | [65] |
| Plasmacytoma variant translocation 1 (PVT1) PVT1 | Chr8q24.21 | 1716 nucleotides | Progression of ovarian cancer is supported by PVT1 by silencing miR-214. | [66] |
| GASS | 1q25.1.10 | 0.7 | The expression of GAS5 is more prevalent in EOC than in normal ovarian epithelium tissue. | [67] |
| Homeobox protein D cluster antisense RNA 1 (HOXD-AS1 | Chr2q31.2 | Raised levels of HOXD-AS1 were adversely correlated with PFS and OS of EOC patients. | [68] | |
| Sprouty RTK signaling antagonist (SPRY4-IT1) | Chr5q31.3 | 708 | Progression of ovarian cancer might occur due to SPRY4-IT1 downregulation [119]. But still, the mechanism of this long codinglncRNAA is complicated, whether it acts as a tumor suppressor or an oncogene in ovarian tissue | [69] |